Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro

The Prostate
R KraaijC H Bangma

Abstract

Adenovirus binds to the coxsackievirus and adenovirus receptor (CAR) as a first step in the process of cellular infection. This dependence on CAR potentially limits the use of adenovirus in gene therapy, since CAR is expressed in many tissues of the body, and expression of CAR may be low or lost upon progression of certain tumors. These limitations may be overcome by transductional targeting of adenovirus towards other cell surface molecules. We have evaluated the pantumoral epithelial cell adhesion molecule (EpCAM) and prostate specific membrane antigen (PSMA) as possible targets for adenoviral transduction of prostate cancer cells. Bispecific antibodies, constructed as conjugates between an anti-adenovirus fiber knob Fab' fragment and anti-EpCAM or anti-PSMA monoclonal antibodies, were incubated with an eGFP-expressing adenovirus to retarget this vector. A cell panel, that includes two prostate cancer cell lines and four non-prostate control lines, were infected with serial dilutions of the retargeted vector and specificity of infection was determined. Receptor-specific transduction was obtained for both EpCAM and PSMA. PSMA-retargeting was shown to be selective for the prostate cancer cell lines. PSMA serves as a tissue-spec...Continue Reading

References

Sep 4, 1995·International Journal of Cancer. Journal International Du Cancer·J K TroyerG L Wright
Jan 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·R E CarterJ T Coyle
Nov 1, 1996·Nature Biotechnology·J T DouglasD T Curiel
Sep 8, 1999·Microbiology and Molecular Biology Reviews : MMBR·G R Nemerow, P L Stewart
Sep 24, 1999·The Journal of Urology·R B PoczatekW E Grizzle
Feb 10, 2000·Experimental Cell Research·R P TomkoL Philipson
Mar 20, 2001·Nature Reviews. Genetics·N Somia, I M Verma
Jul 20, 2001·Journal of Virology·M K MagnussonL Lindholm
Dec 12, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·S A NicklinA H Baker
Jan 17, 2003·The New England Journal of Medicine·Salima Hacein-Bey-AbinaAlain Fischer

❮ Previous
Next ❯

Citations

Nov 22, 2005·Oncogene·J Michael MathisDavid T Curiel
Dec 2, 2009·Human Gene Therapy·Jeroen de VrijGuy Zuber
Dec 25, 2009·Human Gene Therapy·Norman MaitlandUNKNOWN GIANT FP6 Consortium
Feb 9, 2012·Advances in Virology·M H Verheije, P J M Rottier
Apr 26, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marxa L FigueiredoLily Wu
Nov 4, 2008·Expert Opinion on Drug Delivery·Houria BachtarziKerry Fisher
Dec 2, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·W M GommansM G Rots
Nov 16, 2005·BJU International·Chris H BangmaEllen Schenk-Braat
Feb 23, 2007·International Journal of Cancer. Journal International Du Cancer·Tuuli RankiAkseli Hemminki
Apr 4, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark LyonsKerry D Fisher
Jan 19, 2011·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Xiaodong WengHao Shen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.